A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 2
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · SINGLE
- Evidence population
- Human clinical study registration
- Participants
- 158
- Population
- ALL · 55 Years
- Duration
- 2012-01-25 to 2015-06-24
- Intervention
- LFG316; Sham; LFG316 Lower dose
- Comparator
- Not reported
- Outcomes measured
- Part A: Geographic Atrophy (GA) Lesion Growth Measured by Fundus Autofluorescence (FAF) From Baseline to Day 505 — Day…; Part A: Sensitivity Analysis of the Primary End Point: Mixed Effects Model for Repeated Measurements on GA Lesion Growt…; Part B: Safety and Tolerability of a Single Intravitreal (IVT) Dose of 10 mg/100 μL of LFG316 in Patients With Advanced…; Part A: Change From Baseline in GA Lesions Growth Measured by Fundus Autofluorescence — Day 1 to Day 169 and Day 505 (s…; Part A: Change in Best Corrected Visual Acuity (BCVA) as Measured by the EDTRS (Early Treatment of Diabetic Retinopathy…; Part A: Summary of Best Corrected Visual Acuity Over Time, Statistical Analysis of Change in Best Corrected Visual Acui…; Part A: Concentrations of Total LFG316 in Blood During the Course of the Study — Day 1 to Day 559 (starting from the da…; Part A: Concentrations of Total C5 in Blood During the Course of the Study — Day 1 to Day 559 (starting from the day of…; Part B: AUC (Area Under the Curve) - Summary Statistics for PK Parameters — Day 1 to Day 85 (starting from the day of f…; Tmax (hr) — Day 1 to Day 85 (starting from the day of first intravitreal injection to day 85); Part B: Cmax - Summary Statistic for PK Parameters — Day 1 to Day 85 (starting from the day of first intravitreal injec…; Part B: Cmax_D - Summary Statistic for PK Parameters — Day 1 to Day 85 (starting from the day of first intravitreal inj…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.
Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.